Objective To explore the clinical efficacy of sacubitril/valsartan combined with crea-tine phosphate sodium in heart failure patients with reduced ejection fraction(HFrEF).Methods A total of 116 patients with HFrEF were randomly divided into combination group and control group,with 58 cases in each group.The control group was treated with sacubitril/valsartan,while the combi-nation group was treated with sacubitril/valsartan and creatine phosphate sodium.Both groups were continually treated for 8 weeks.The clinical efficacy,oxidative stress indicators,cardiac function indicators,vascular endothelial function indicators and myocardial injury indicators before treatment and at 4 and 8 weeks after treatment as well as the occurrence of adverse reactions were compared between the two groups.Results The total effective rate was 94.83％in the combination group,which was significantly higher than 81.03％in the control group(P＜0.05).At 4 and 8 weeks of treatment,the left ventricular end-systolic diameter(LVESD)and left ventricular end-diastolic diam-eter(LVEDD)in the combination group were significantly lower than those in the control group,while the left ventricular ejection fraction(LVEF)was significantly higher than that in the control group(P＜0.01);the thromboxane B2(TXB2)and endothelin-1(ET-1)levels in the combination group were significantly lower than those in the control group,while the vascular endothelial growth factor(VEGF)level was significantly higher than that in the control group(P＜0.01);the levels of car-diac troponin Ⅰ(cTnⅠ),heart-type fatty acid-binding protein(H-FABP)and N-terminal pro-brain natriuretic peptide(NT-proBNP)in the combination group were significantly lower than those in the control group(P＜0.01).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Sacubitril/valsartan combined with creatine phosphate sodium has a definite therapeutic effect in treating patients with HFrEF,which can regu-late the degree of oxidative stress,improve vascular endothelial function,and thus promote the re-covery of cardiac function.

With continuous discovery of tumor immune targets and continuous changes in antibody research and development technology, antibody drugs are becoming more and more widely used in clinical practice. However, some targets are not only expressed on tumor cells, but also on red blood cells. Therefore, the clinical application of antibodies against the corresponding targets may interfere with the detection of blood transfusion compatibility, resulting in difficulty in blood matching or delay of blood transfusion. This consensus summarizes the current solutions for the interference of CD38 monoclonal antibody (CD38 mAb) in transfusion compatibility testing. After analyzing the advantages and disadvantages of different methods, polybrene and sulfhydryl reducing agents [dithiothreitol (DTT) or 2-mercaptoethanol (2-Me)], as a solution for CD38 mAb interference in blood compatibility testing, are recommended for Chinese patients, so as to eliminate blood transfusion interference produce by CD38 mAb and further provide a pre-transfusion workflow for clinicians and technicians in Department of Blood Transfusion.